UNITY is a leading biotechnology company that is committed to developing a new class of therapeutics to slow, halt or reverse diseases of aging. It works at the frontier of biotechnology and medicine to extend the period of one’s life unburdened by disease. Its current focus is on producing medicines to particularly eliminate or modulate aging cells and consequently provide transformative benefit in age-related ophthalmologic and neurologic diseases.
UNITY is developing therapeutics that target aging and adjacent biology with general application across multiple indications with established endpoints and well-defined regulatory pathways to approval. Its initial focus is on delivering localized therapy in ophthalmologic and neurologic diseases.